US4264449A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Antibody-specific solid phase immunoadsorbent, preparation thereof, and antibody purification therewith
Assignee: American Red Cross
•
Filing: 1980-01-28
•
Granted: 1981-04-28
•
Expires: 2000-01-28
Abstract
Abstract An antibody-specific solid phase immunoadsorbent is prepared by adsorptively binding a lipid-containing viral antigen, such as hepatitis B surface antigen, to the surface of a porous glass carrier having an average pore diameter within the range of about 40-200 nm and an adsorptive surface which within the pH range of 2-8 is capable of selectively and stably binding lipid-containing materials, employing an adsorption buffer having a pH within such range. The high adsorptive selectivity of the carrier surface for the antigen under such conditions, enables preparation of the immunoadsorbent directly from whole human plasma containing the antigen, without the necessity for prior antigen purification. The resultant immunoadsorbent has a high complexing specificity, efficiency and capacity for the specific antibody to the bound antigen, is capable of providing a reasonably high yield of the specific antibody, and is stable under the conditions required for antibody-antigen complexing and dissociation, thereby rendering it highly effective for the isolation and purification of the specific antibody by affinity chromatography techniques. A specific application of the methods and materials described which is of particular clinical significance is in providing a relatively simple and inexpensive procedure for recovering purified hepatitis B antibody from standard immune serum globulin.
Inventors
- 👤 Roger Y. Dodd
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 15:28
CPC Classifications
B; B01; B01D; B01D15/00; B01D15/08; B01D15/26; B01D15/38; B01D15/3804; B01D15/3809; B01J; B01J20/00; B01J20/28; B01J20/28002; B01J20/28004; B01J20/28054; B01J20/28078; B01J20/281; B01J20/286; B01J20/30; B01J20/3092; B01J20/32; B01J20/3202; B01J20/3204; B01J20/3231; B01J20/3242; B01J20/3268; B01J20/3272; B01J20/3274; B01J20/34; B01J20/3425; B01J20/345; B01J20/3475; C; C07; C07K; C07K16/00; C07K16/08; C07K16/081; C07K16/082; B01D15/42; B01D15/424; B01D15/426; B01J2220/00; B01J2220/50; B01J2220/54; B01J2220/56; B01J2220/58
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
189 words
An affinity chromatography method for the isolation and purification of a specific antibody from a preparation containing said antibody, comprising the steps of: (a) preparing a solution of said antibody preparation in a neutral pH isotonic complexing buffer; (b) contacting the resulting antibody solution with a solid phase immunoadsorbent comprising a porous glass carrier having an average pore diameter within the range of about 40-200 nm and an adsorptive surface which within the pH range of about 2-8 is capable of selectively and stably binding lipid-containing materials, and a lipid-containing viral antigen specific to said specific antibody adsorptively bound to said carrier surface, so as to effect selective complexing of said specific antibody with the antigen moiety of said immunoadsorbent; (c) washing said immunoadsorbent with an additional amount of said complexing buffer so as to effect removal therefrom of any residual uncomplexed material; and (d) eluting said specific antibody from said immunoadsorbent with an elution buffer capable of dissociating the complex of said specific antibody with said antigen moiety without effecting release of said antigen moiety from said carrier surface or destruction of the integrity of the eluted antibody.
Claim 2
Dependent Claim
189 words
An affinity chromatography method for the isolation and purification of a specific antibody from a preparation containing said antibody, comprising the steps of: (a) preparing a solution of said antibody preparation in a neutral pH isotonic complexing buffer; (b) contacting the resulting antibody solution with a solid phase immunoadsorbent comprising a porous glass carrier having an average pore diameter within the range of about 40-200 nm and an adsorptive surface which within the pH range of about 2-8 is capable of selectively and stably binding lipid-containing materials, and a lipid-containing viral antigen specific to said specific antibody adsorptively bound to said carrier surface, so as to effect selective complexing of said specific antibody with the antigen moiety of said immunoadsorbent; (c) washing said immunoadsorbent with an additional amount of said complexing buffer so as to effect removal therefrom of any residual uncomplexed material; and (d) eluting said specific antibody from said immunoadsorbent with an elution buffer capable of dissociating the complex of said specific antibody with said antigen moiety without effecting release of said antigen moiety from said carrier surface or destruction of the integrity of the eluted antibody.
Claim 3
Dependent Claim
13 words
The method of claim 1, wherein said antibody preparation is immune serum globulin.
Claim 4
Dependent Claim
15 words
The method of claim 1, wherein said complexing buffer is phosphate buffered saline, pH 7-7.2.
Claim 5
Dependent Claim
61 words
The method of claim 1, wherein said eluting of said antibody from said immunoadsorbent is effected with a low pH elution buffer; and prior to its being contacted with said antibody solution, said immunoadsorbent is subjected to a pretreatment comprising a first prewash with a buffer of lower pH than said elution buffer, and a subsequent prewash with said complexing buffer.
Claim 6
Dependent Claim
66 words
The method of claim 1, wherein said eluting of said antibody from said immunoadsorbent is effected with an elution buffer of high chaotropic ion concentration; and prior to its being contacted with said antibody solution, said immunoadsorbent is subjected to a pretreatment comprising a first prewash with a buffer of higher chaotropic ion concentration than said elution buffer, and a subsequent prewash with said complexing buffer.
Claim 7
Dependent Claim
17 words
The method of claim 1, wherein said antigen moiety of said immunoadsorbent is hepatitis B surface antigen.
Claim 8
Dependent Claim
13 words
The method of claim 6, wherein said antibody preparation is immune serum globulin.
Claim 9
Dependent Claim
19 words
The method of claim 6, wherein said porous glass carrier has an average pore diameter of about 150 nm.
Claim 10
Dependent Claim
33 words
The method of claim 6, wherein said elution buffer is selected from the group consisting of glycine-HCl buffer, pH 2.8; citrate-HCl buffer, pH 2.8; 4 M sodium thiocyanate; and 4 M potassium bromide.
Claim 11
Dependent Claim
43 words
The method of claim 9, wherein said elution buffer is 0.1 M citrate-HCl buffer, pH 2.8; and said immunoadsorbent is subjected to a pretreatment comprising a first prewash with 0.1 M citrate-HCl buffer, pH 2.5, and a subsequent prewash with said complexing buffer.
Claim 12
Dependent Claim
48 words
The method of claim 9, wherein said elution buffer is 4 M potassium bromide; and prior to its being contacted with said antibody solution, said immunoadsorbent is subjected to a pretreatment comprising a first prewash with 4.5 M potassium bromide, and a subsequent prewash with said complexing buffer.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-04-27 | 1984-10-27 | 1985-04-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-04-27 | 1988-10-27 | 1989-04-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-04-27 | 1992-10-27 | 1993-04-28 | $7700.00 | Window Closed / Lapsed |